부산대학교 도서관

ProxyOFF
KOR
Home
Total Search
e-Article

e-Article

replayBack to search results
searchSearch screen
A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.
Document Type
article
Author
Parsons, J Kellogg; Pinto, Peter A; Pavlovich, Christian P; Uchio, Edward; Kim, Hyung L; Nguyen, Mikel N; Gulley, James L; Jamieson, Christina; Hsu, Paul; Wojtowicz, Margarita; Parnes, Howard; Schlom, Jeffrey; Dahut, William L; Madan, Ravi A; Donahue, Renee N; Chow, H-H Sherry
Source
European urology focus. 4(5)
Subject
Humans
Prostatic Neoplasms
Disease Progression
Prostate-Specific Antigen
Cancer Vaccines
Immunologic Factors
Treatment Outcome
Immunotherapy
Follow-Up Studies
Aged
Middle Aged
Male
Neoplasm Grading
Cancer
Immunization
Prostate Cancer
Clinical Trials and Supportive Activities
Prevention
Aging
Urologic Diseases
Clinical Research
Vaccine Related
6.1 Pharmaceuticals
Evaluation of treatments and therapeutic interventions
Clinical Sciences
Language
Abstract
The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5mo. Final results will be available in 2019.

Online Access

Open Access (eScholarship) Find it@PNU

Send an e-mail

이메일

폴더 추가